FDA Breakthrough status for Immunomedics breast cancer candidate

This entry was posted by ctbenefits on February 6, 2016 at 12:48 AM

The company's sacituzumab govitecan, or IMMU-132, has received this designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease. The Breakthrough …